1.Török, TJ. Parvovirus B19 and human disease. Adv Intern Med 1992;37:431–455.
2.Brown, KE, Young, NS, Liu, JM. Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit Rev Oncol Hematol 1994;16:1–31.
3.Chorba, T, Coccia, P, Holman, RC. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986;154:383–393.
4.Frickhofen, N, Abkowitz, JL, Safford, M, et al. Persistent B19 par-vovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990;113:926–933.
5.Public Health Laboratory Service Working Party on Fifth Disease. Prospective study of human parvovirus (B19) infection in pregnancy. Br Med J 1990;300:1166–1170.
6.Török, TJ. Human parvovirus B19. In: Remington, JS, Klein, JO, eds. Infectious Diseases of the Fetus and Newborn Infant. 4th ed. Philadelphia, PA: W.B. Saunders; 1995:668–702.
7.Anderson, MJ, Higgins, PG, Davis, LR, et al. Experimental par-vovirus infection in humans. J Infect Dis 1985;152:257–265.
8.Centers for Disease Control. Risks associated with human par-vovirus B19 infection. MMWR 1989;38:81-88,93–97.
9.Evans, JPM, Rossiter, MA, Kumaran, TO, Marsh, GW. Human parvovirus aplasia: case due to cross infection in a ward. Br Med J 1984;288:681.
10.Bell, LM, Naides, SJ, Stoffman, P, Hodinka, RL, Plotkin, SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 1989;321:485–491.
11.Pillay, D, Patou, G, Hurt, S, Kibbler, CC, Griffiths, PD. Parvovirus B19 outbreak in a children's ward. Lancet 1992;339:107–109.
12.Seng, C, Watkins, P, Morse, D, et al. Parvovirus B19 outbreak on an adult ward. Epidemiol Infect 1994;113:345–353.
13.Shishiba, T, Matsunaga, Y. An outbreak of erythema infectiosum among hospital staff members including a patient with pleural fluid and pericardial effusion. J Am Acad Dermatol 1993;29:265–267.
14.Dowell, SF, Török, TJ, Thorp, JA, et al. Parvovirus B19 infection in hospital workers: community or hospital acquisition. J Infect Dis 1995;172:1076–1079.
15.Erdman, DD, Usher, MJ, Tsou, C, et al. Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol 1991;35:110–115.
16.Kajigaya, S, Fujii, H, Field, A, et al. Self-assembled B19 par-vovirus capsids, produced in a baculovirus system, are anti-genically and immunologically similar to native virus. Proc Natl Acad Sci USA 1991;88:4646–4650.
17.Koziol, DE, Kurtzman, G, Ayub, J, Young, NS, Henderson, DK. Nosocomial human parvovirus B19 infection: lack of transmission from a chronically infected patient to hospital staff. Infect Control Hosp Epidemiol 1992;13:343–348.
18.Frickhofen, N, Young, NS. Persistent parvovirus B19 infection in humans. Microb Pathog 1989;7:319–327.
19.Naides, SJ. Infection control measures for human parvovirus B19 in the hospital setting. Infect Control Hosp Epidemiol 1989;10:326–329.